GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but ...
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS), according to ...
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Health News // 4 hours ago Medicaid covers GLP-1 weight-loss drugs in just 13 states Only 13 states currently allow ...
For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor ...
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.